While the socio-economic impact of translational medicine is the most obvious, EATRIS’ efforts serving industry since its inception should be celebrated reducing barriers to public-private collaboration, and knowledge sharing. Additional efforts to be highlighted include to the mentoring and translational services offered to SMEs. Although the services are delivered to researcher funders, start-ups and biotech companies are the main beneficiary, provided with strong knowledge and support for their products portfolio development, strong understanding of IP and market analysis together with regulatory and health technology assessment expertise.
To evidence EATRIS’ contribution to boosting the economy, we track key performance indicators that reflect how EATRIS supports industry engagement and facilitates access to specialised translational expertise. In 2025, 212 users accessed EATRIS services. EATRIS delivered research services to a wide range of users, including 31 companies, from large pharma to SMEs and biotech companies. The total value of services provided in 2025 was €339,180.00. Since 2014, 981 users have accessed EATRIS services. Over this period, EATRIS delivered research services to 200 companies, including large pharma, SMEs and biotech companies, with a total service value of €3,873,992.50.
Examples of our work in this area:
Swedish biotech UmanDiagnostics finds new collaborators through EATRIS support
UmanDiagnostics, a leader in neurological disease diagnostics, shares how a presentation in Umeå sparked a valuable collaboration journey through EATRIS.
Innovation Hubs: EATRIS and GSK extend their collaboration for three additional years
EATRIS-ERIC, GSK and five EATRIS member institutions are collaborating for the advancement of molecular imaging tools, joining forces under a novel international public-private partnership: The Translational Molecular Imaging Hub.
EATRIS providing expert advice to impact investment fund Human Plus
Human Plus supporting bringing early innovations to patients faster teams up with EATRIS for its projects’ translational potential-, health technology- and regulatory assessments.
European Commission selects EATRIS best practices for EU knowledge valorisation platform
European Commission selects the public-private collaboration workshop, and the GSK Innovation Hub as examples of Best Practice on the EU Knowledge Valorisation Platform
Concluding the Journey of the EATRIS-GSK Imaging Hub
The GlaxoSmithKline (GSK) Translational Molecular Imaging Hub, a pioneering public-private partnership developed by EATRIS and GSK, will soon be concluding. Since its inception in 2018, this collaborative imaging Hub has united scientific and clinical experts to advance innovative imaging methods for inflammatory diseases, achieving progress in translating research findings into clinical applications.
